Inj, taliglucerase alfa 10 u
Products billed under this code include Elelyso.
Payment limit per 10 UNITS, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Elelyso.
Payment limit per 10 UNITS, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Elelyso | Pfizer Inc | 00069-0106-01 | 20 | $849.46 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $42.473 | −$0.202 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted September 17, 2026 |
| 3Q26 | $42.675 | +$2.018 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted September 15, 2026 |
| 2Q26 | $40.657 | −$0.286 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted September 15, 2026 |
| 1Q26 | $40.943 | −$0.167 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted September 15, 2026 |
| 4Q25 | $41.11 | +$0.046 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted September 8, 2026 |
| 3Q25 | $41.064 | +$0.422 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted March 10, 2026 |
| 2Q25 | $40.642 | −$0.979 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted March 10, 2026 |
| 1Q25 | $41.621 | −$0.96 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted December 19, 2025 |
| 4Q24 | $42.581 | −$1.989 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 11, 2025 |
| 3Q24 | $44.57 | −$0.43 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 11, 2025 |
| 2Q24 | $45.00 | −$0.034 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted March 11, 2025 |
| 1Q24 | $45.034 | −$0.141 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted December 19, 2024 |
| 4Q23 | $45.175 | +$0.614 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted October 10, 2024 |
| 3Q23 | $44.561 | +$1.645 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 5, 2024 |
| 2Q23 | $42.916 | +$0.921 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted February 23, 2024 |
| 1Q23 | $41.995 | +$0.092 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted December 6, 2023 |
| 4Q22 | $41.903 | +$0.218 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 22, 2023 |
| 3Q22 | $41.685 | +$1.333 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 9, 2023 |
| 2Q22 | $40.352 | −$0.877 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted December 14, 2022 |
| 1Q22 | $41.229 | −$0.093 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 8, 2022 |
| 4Q21 | $41.322 | −$0.058 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 2, 2022 |
| 3Q21 | $41.38 | +$0.305 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted June 2, 2022 |
| 2Q21 | $41.075 | +$0.111 | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted March 1, 2022 |
| 1Q21 | $40.964 | – | 10 UNITS | Inj, taliglucerase alfa 10 u | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.